Mar 23, 2024
The 8th Annual Frontiers in Therapeutics and Diagnostics (FTD) Forum
SABPA FTD annually brings together the latest in groundbreaking research, cutting-edge drugs, and industry trends within the biopharma sector. The event's broad spectrum of topics provides a platform for local biotech companies to engage in vibrant discussions and valuable networking opportunities. The forthcoming 8th FTD Conference is set to shine a spotlight on three revolutionary domains in the field of metabolism disease and oncology: Glucagon-like peptide-1 (GLP-1), Antibody-Drug Conjugates (ADC), and Minimal Residual Disease (MRD), each representing the forefront of innovations in therapeutics and diagnostics.
This event is over.
Date and Time
March 23, 2024, 8:00 am - 5:00 pmLocation
Hilton San Diego/Del Mar 15575 Jimmy Durante Boulevard Del Mar, CA 92014Refund Policy
You may cancel your registration up to 3 days before the event. Regrettably, we will not be able to refund your registration fee, but you may request a credit to be used towards payment for our future events or membership enrollment/renewal. Please email your request or questions to noreply@sabpa.org.
About this Event
SABPA Frontiers in Therapeutics and Diagnostics (FTD) Forum
Date: Saturday, March 23rd
Address: Hilton San Diego/Del Mar 15575 Jimmy Durante Boulevard Del Mar, CA 92014
Highlighted topics:
-
The realm of diabetes management is witnessing a paradigm shift with GLP-1 inhibitors, a class of drugs demonstrating remarkable efficacy in regulating blood sugar levels. We are thrilled to announce that Dr. Lotte Bjerre Knudsen, Chief Scientific Advisor at Novo Nordisk, will be our keynote speaker in this session.
-
ADCs are a rapidly emerging class of therapeutic agents that combine the target specificity of a monoclonal antibody (mAb) with the lethality of cytotoxic cellular poison. This orchestrated synergy enables a precise attack on specific cells while sparing healthy ones, facilitating more precise and effective treatments for various cancers.
-
The concept of MRD has emerged as a game-changer in cancer therapeutics. By detecting and targeting residual cancer cells that may linger post-treatment, MRD assessments offer a clearer understanding of disease progression and treatment response.
Highlighted speakers:
-
Lotte Knudsen, Chief Scientific Advisor, Novo Nordisk
-
Shawn Zhang, CSO, General Manager China AMBRX
-
David Maggs, CEO and Founder, Avance Therapeutics
-
Alan Jiang, Chief Strategy Officer, XtalPi Inc.
-
Tyler Stewart, Medical Oncologist, UCSD
In addition to our compelling lineup of presentations, the 2024 SABPA FTD Conference will feature a dynamic Poster Session, adding a unique dimension to the event.
We extend an invitation to postdocs, graduate students, and research professionals from local institutes and universities to showcase their innovative research, fostering collaborations and sharing discoveries. To honor excellence in poster presentations, we are proud to introduce two awards: the Investigator Award and the Most Popular Award.
Submit your poster abstract: https://docs.google.com/forms/d/e/1FAIpQLSdqgzPuuUAmWqMHePb0V0Den8wGoG-_IOpPOcnMl05A5Z7Uxg/viewform?usp=sf_link
Below is the event flyer:
